Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.74 |
| ▸ | BACE1 | P56817 | 11/20 | 0.74 |
| ▸ | AURKA | O14965 | 5/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.64 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.60 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12255609 | 0.90 | ACHE (0.73) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL11882354 | 0.88 | ACHE (0.88) | ACHEBACE1AURKAPDE10AENPP1 | |
| Hydrochloric Acid SCHEMBL20771436 | 0.88 | ACHE (0.70) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL22300095 | 0.86 | ACHE (0.69) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL22435916 | 0.85 | ACHE (0.67) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL13790502 | 0.85 | ACHE (1.00) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL23727018 | 0.84 | ENPP1 (0.69) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL30080162 | 0.84 | ENPP1 (0.69) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL20813424 | 0.83 | ENPP1 (0.72) | ACHEBACE1AURKAPDE10AENPP1 | |
| SCHEMBL20782683 | 0.83 | ACHE (0.65) | ACHEBACE1AURKAPDE10AENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ACHE 2363/4885BACE1 1830/4885AURKA 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.